|Bid||90.23 x 100|
|Ask||95.59 x 100|
|Day's Range||92.33 - 96.70|
|52 Week Range||11.57 - 96.92|
|PE Ratio (TTM)||-11.69|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||92.73|
For bright investors in search of some new ideas here are three stocks worth a good look.
This healthcare ETF hit a new 52-week high. Are more gains in store for this ETF?
One day after announcing good results of a trial of its ovarian cancer drug rucaparib, Clovis Oncology Inc. said it's commencing a $250 million public offering of its stock. Clovis will use the money for sales and marketing of its drug rucaparib, both in the United States and, if approved by the European Medicines Agency, in Europe, as well as to fund the compay's drug development programs, general and administrative expenses, and possible acquisitions or licensing of of new drug candidates, the Boulder biotech said in a statement. Reaction to the stock offering is positive enough that the investment banks underwriting it exercised their option to purchase an additional 511,363 shares, Clovis said Thursday.